The most recent issue of the journal Frontiers presents findings of the first pharmacokinetic study and clinical trial on the use of cannabinoids to treat dogs with osteoarthritis and multi-joint pain.
The objective of this double-blind, placebo-controlled study was to “determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA).”
In conducting their study, researchers found that “canine brief pain inventory and Hudson activity scores showed a significant decrease in pain and increase in activity with CBD oil.” Veterinary assessment “showed decreased pain during CBD treatment”, while “No side effects were reported by owners”.
Researchers state that “This pharmacokinetic and clinical study suggests that 2 mg/kg of CBD twice daily can help increase comfort and activity in dogs with OA [osteoarthritis].”
The full study, including its abstract, can be found by clicking here.